A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder

被引：0
|
作者：
Soyon Lee
Bimal Malhotra
Dana Creanga
Martin Carlsson
Paul Glue
机构：
[1] Rutgers University,Ernest Mario School of Pharmacy
[2] Pfizer Inc,Clinical Pharmacology Department
[3] Pfizer Inc,Statistics Department
[4] Dunedin School of Medicine,undefined
来源：
BMC Medical Research Methodology | / 9卷
关键词：
Stress Urinary Incontinence; Overactive Bladder; Oxybutynin; Tolterodine; Placebo Response;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Placebo response rates in clinical trials. A meta-analysis
    Maidhof, CH
    Dehm, C
    Walach, H
    INTERNATIONAL JOURNAL OF PSYCHOLOGY, 2000, 35 (3-4) : 224 - 224
  • [32] Urodynamic verification of an overactive bladder is not a prerequisite for antimuscarinic treatment response
    Malone-Lee, J
    Henshaw, DJE
    Cummings, K
    BJU INTERNATIONAL, 2003, 92 (04) : 415 - 417
  • [33] Nocebo Response in the Pharmacological Management of Overactive Bladder: A Systematic Review and Meta-analysis
    Mostafaei, Hadi
    Mori, Keiichiro
    Quhal, Fahad
    Miura, Noriyoshi
    Motlagh, Reza Sari
    Pradere, Benjamin
    Laukhtina, Ekaterina
    Lysenko, Ivan
    Ghaffari, Sajjad
    Hajebrahimi, Sakineh
    Shariat, Shahrokh F.
    EUROPEAN UROLOGY FOCUS, 2021, 7 (05): : 1143 - 1156
  • [34] Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis
    Kelleher, Con
    Hakimi, Zalmai
    Zur, Richard
    Siddiqui, Emad
    Maman, Khaled
    Aballea, Samuel
    Nazir, Jameel
    Chapple, Chris
    EUROPEAN UROLOGY, 2018, 74 (03) : 324 - 333
  • [35] A meta-analysis comparing trials of antimuscarinic medications funded by industry or not
    Tulikangas, Paul K.
    Ayers, Amanda
    O'Sullivan, David M.
    BJU INTERNATIONAL, 2006, 98 (02) : 377 - 380
  • [36] Antimuscarinic drug therapy for overactive bladder syndrome in the elderly - are the concerns justified?
    Khastgir, Jay
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (07) : 813 - 820
  • [37] Are effects of antimuscarinic drug treatment for overactive bladder enough to make a difference?
    Larsson, G
    Jansson, G
    Hooper, UR
    Wein, A
    JOURNAL OF UROLOGY, 1998, 159 (05): : 35 - 35
  • [38] THE ROLE OF INDUSTRY FUNDING IN RANDOMIZED CONTROLLED TRIALS OF ANTIMUSCARINIC MEDICATIONS FOR OVERACTIVE BLADDER
    Clemens, J. Q.
    NEUROUROLOGY AND URODYNAMICS, 2009, 28 (07) : 727 - 727
  • [39] Solifenacin for overactive bladder: a systematic review and meta-analysis
    Deyi Luo
    Liangren Liu
    Ping Han
    Qiang Wei
    Hong Shen
    International Urogynecology Journal, 2012, 23 : 983 - 991
  • [40] Solifenacin for overactive bladder: a systematic review and meta-analysis
    Luo, Deyi
    Liu, Liangren
    Han, Ping
    Wei, Qiang
    Shen, Hong
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2012, 23 (08) : 983 - 991
12345